Programmed Death-Ligand 1
Programmed death-ligand 1 (PD-L1), also known as B7-H1 and encoded by CD274, is a cell-surface immune-regulatory protein that participates in the PD-1/PD-L1 immune checkpoint.
Programmed death-ligand 1 (PD-L1), also known as B7-H1 and encoded by CD274, is a cell-surface immune-regulatory protein that participates in the PD-1/PD-L1 immune checkpoint. Engagement of PD-L1 with programmed cell death protein 1 (PD-1) can inhibit T-cell function, making the pathway an important mechanism by which tumor cells and the tumor microenvironment suppress antitumor immunity. Accordingly, PD-L1 is investigated as a biomarker of immune activity and prognosis, as well as a therapeutic target in immunotherapy for cancer.
Current research is extending PD-L1 biology beyond ligand-mediated immune suppression. Studies are examining its regulation by miRNAs, protein ubiquitination and deubiquitination, oncogenic signaling, and tumor metabolism. Other work is developing direct PD-1/PD-L1 inhibitors, PD-L1-targeted imaging agents, and combination approaches pairing PD-L1 blockade with chemotherapy, radiotherapy, radionuclide therapy, angiogenesis inhibition, or other immune checkpoint interventions. These efforts seek to improve responses in solid tumors, counter resistance to anti-Programmed Cell Death Protein-1 Therapy, and clarify how PD-L1 expression relates to survival and disease-free survival.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
13 papers study programmed death-ligand 1 directly. The themes below are drawn from those 13. 1 new direction follows.
-
PD-1/PD-L1 Therapeutic Strategies : PD-1/PD-L1 research links miRNA, PRKX and PDK4/GLS metabolism to immune suppression and anti-PD-1 resistance. Small-molecule inhibitors, cyclic peptides and 89Zr-atezolizumab imaging extend this biology toward drug discovery and response assessment. 6 papers · 46.2%
-
Combination Cancer Immunotherapy : PD-L1 blockade is being paired with integrin α2 inhibition, targeted radionuclide therapy, chemotherapy and local nanoplatforms to intensify antitumor immunity. Angiogenesis control and immune remodeling recur as routes to convert poorly immunogenic or metastatic tumors into treatment-responsive disease. 5 papers · 38.5%
-
PD-L1 in Squamous Carcinoma : PD-L1 is linked to immune evasion in cervical and oral squamous carcinomas, with GMPS promoting PD-L1 through USP7-mediated deubiquitination. Clinical cohorts connect PD-L1 expression with outcomes, supporting biomarker-guided study of squamous cancers. 2 papers · 15.4%
PD-L1 functions as a tumor-intrinsic metabolic signaling molecule that drives anti-PD-1 resistance
In non-small cell lung cancer models of anti-PD-1 resistance, PD-L1 was treated not only as a ligand that suppresses T-cell activity but also as a signaling molecule within tumor cells. The study found that antibody-mediated PD-L1 ligation activates a PDK4/GLS metabolic axis associated with pyruvate accumulation and resistance to anti-PD-1 therapy, and that targeting this axis restores therapeutic sensitivity. This assigns PD-L1 a tumor-intrinsic metabolic role beyond immune-checkpoint inhibition, biomarker status, or regulation of its abundance, redirecting treatment toward the downstream metabolic circuitry as well as the checkpoint itself. 42686373Sep
Recent Findings on Programmed Death-Ligand 1
PD-L1 Therapeutic Targeting: Quaternary ammonium chemistry and protein–protein interaction design are improving direct PD-1/PD-L1 inhibition. QA9 increased water solubility 600-fold, stabilized the PD-L1 dimer, enhanced immune-mediated tumor cell death, and suppressed angiogenic activity in preclinical models 42720488Sep, while HighMorph generated active PD-L1-binding cyclic peptides with micromolar affinities 42720486Sep. Tumor-intrinsic regulation also shapes treatment resistance: PRKX stabilizes PD-L1 through phosphorylation-dependent inhibition of ubiquitination, whereas PD-L1 ligation activates the PDK4/GLS metabolic axis and promotes macrophage senescence 42716706Sep42686373Sep. PRKX-targeting small interfering RNA and PDK4 or GLS inhibition restored antitumor activity in mouse models, supporting combination strategies with anti-PD-1 therapy 42716706Sep42686373Sep. Conserved miRNAs and 89Zr-DFO-atezolizumab are being developed as complementary biomarkers, although miR-138-5p showed survival associations opposite to those of several other miRNAs, and immuno-PET remains preclinical 42616478Aug42119829May.
Combination Cancer Immunotherapy: CD49b blockade, targeted radionuclide therapy, vaccination, chemotherapy, and tumor-targeted nanoplatforms all aim to increase immune activation alongside PD-L1 inhibition. In the 4T1 breast cancer model, CD49b blockade increased CD8+ T-cell and dendritic cell infiltration while reducing immunosuppressive myeloid populations and synergizing with PD-L1 inhibition 42747603Sep. Low-dose targeted radionuclide therapy combined with anti-PD-L1, anti-CTLA-4, and in situ vaccination eradicated established tumors, prevented lung metastases, and generated tumor-specific immune memory in mice 42418729Jul. Mn-PC-PTX and DOX@MZIF-P3 paired immunogenic cell death with COX-2 suppression, cGAS-STING activation, pyroptosis, ferroptosis, or apoptosis to improve immune infiltration and inhibit metastasis 42102776May41962221Apr. Lenvatinib with radiotherapy and PD-L1 blockade shows similar preclinical promise in lung adenocarcinoma, but clinical translation requires biomarker-driven trials, functional imaging, circulating biomarkers, and immune monitoring 42708433Sep.
PD-L1 in Squamous Carcinoma: GMPS and USP7 promote PD-L1 stability in cervical squamous cell carcinoma, enabling tumor proliferation, CD8+ T-cell dysfunction, and immune evasion. GMPS knockdown reduced PD-L1 protein levels, while USP7 silencing increased PD-L1 ubiquitination and reduced its stability, identifying the GMPS–USP7–PD-L1 pathway as a therapeutic target 42704520Sep. In contrast, a large oral squamous cell carcinoma cohort found no robust association between PD-L1 expression at CPS ≥ 10 or CPS ≥ 20 and survival or recurrence outcomes 42665707Aug. The isolated survival association at CPS ≥ 1 was driven by a small PD-L1-negative group, so short-term postoperative data do not support PD-L1 as a standalone prognostic marker 42665707Aug.
Written from 13 PubMed abstracts, each one cited by PMID above. Published: 2026-09-11. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.